Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.47 USD | +0.76% | +0.63% | +513.93% |
May. 09 | Landos Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 02 | North American Morning Briefing : Stocks Seen -2- | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 70.24M |
---|---|---|---|---|---|
Net income 2024 * | -26M | Net income 2025 * | -46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 72.5M | Net cash position 2025 * | 30M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.56
x | P/E ratio 2025 * |
-13.3
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.54% |
1 day | +0.76% | ||
1 week | +0.63% | ||
Current month | +0.76% | ||
1 month | +3.31% | ||
3 months | +301.25% | ||
6 months | +445.39% | ||
Current year | +513.93% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Oakes
CEO | Chief Executive Officer | 56 | 22-06-20 |
Claudia Lopez
CTO | Chief Tech/Sci/R&D Officer | - | 22-12-31 |
Dawn Louro
CTO | Chief Tech/Sci/R&D Officer | - | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 57 | 17-08-31 | |
Tim Mayleben
BRD | Director/Board Member | 63 | 21-05-12 |
Alka Batycky
BRD | Director/Board Member | 54 | 23-05-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 22.47 | +0.76% | 12,928 |
24-05-16 | 22.3 | 0.00% | 5,739 |
24-05-15 | 22.3 | -0.67% | 12,273 |
24-05-14 | 22.45 | +1.10% | 2,461 |
24-05-13 | 22.2 | -0.56% | 3,896 |
Delayed Quote Nasdaq, May 17, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+513.93% | 70.24M | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B | |
-6.26% | 11.42B |
- Stock Market
- Equities
- LABP Stock